Literature DB >> 12608697

Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits.

Andrea Schmitt1, Mathias Zink, Bettina Müller, Brigitte May, Anne Herb, Alexander Jatzko, Dieter F Braus, Fritz A Henn.   

Abstract

Postmortem studies in schizophrenic patients revealed alterations in NMDA receptor binding and gene expression of specific subunits. Because most of the patients had been treated with antipsychotics over long periods, medication effects might have influenced those findings. We treated animals with haloperidol and clozapine in clinical doses to investigate the effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Rats were treated with either haloperidol (1.5 mg/kg/day) or clozapine (45 mg/kg/day) given in drinking water over a period of 6 months. Quantitative receptor autoradiography with [3H]-MK-801 was used to examine NMDA receptor binding. In situ hybridization was performed for additional gene expression studies of the NR1, NR2A, NR2B, NR2C, and NR2D subunits. [3H]-MK-801 binding was found to be increased after haloperidol treatment in the striatum and nucleus accumbens. Clozapine was shown to up-regulate NMDA receptor binding only in the nucleus accumbens. There were no alterations in gene expression of NMDA subunits in any of the three regions. However, the NR2A subunit was down-regulated in the hippocampus and prefrontal cortex by both drugs, whereas only clozapine induced a down-regulation of NR1 in the dorsolateral prefrontal cortex. NR2B, 2C, and 2D subunits did not differ between treatment groups and controls. Both altered NMDA receptor binding and subunit expression strengthen a hyperglutamatergic function after haloperidol treatment and may contribute to some of our postmortem findings in antipsychotically treated schizophrenic patients. Because the effects seen in different brain areas clearly vary between haloperidol and clozapine, they may also be responsible for some of the differences in efficacy and side effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12608697     DOI: 10.1023/a:1022325116309

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

1.  Visualizing fronto-striatal circuitry and neuroleptic effects in schizophrenia.

Authors:  M S Buchsbaum; E A Hazlett; M M Haznedar; J Spiegel-Cohen; T C Wei
Journal:  Acta Psychiatr Scand Suppl       Date:  1999

2.  Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.

Authors:  J T Noga; T M Hyde; M M Herman; C F Spurney; L B Bigelow; D R Weinberger; J E Kleinman
Journal:  Synapse       Date:  1997-11       Impact factor: 2.562

3.  NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia.

Authors:  C Humphries; A Mortimer; S Hirsch; J de Belleroche
Journal:  Neuroreport       Date:  1996-08-12       Impact factor: 1.837

4.  Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics.

Authors:  B P Sokolov
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

Review 5.  Glycine agonists: what can they teach us about schizophrenia?

Authors:  N B Farber; J W Newcomer; J W Olney
Journal:  Arch Gen Psychiatry       Date:  1999-01

6.  Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients.

Authors:  M I Aparicio-Legarza; B Davis; P H Hutson; G P Reynolds
Journal:  Neurosci Lett       Date:  1998-01-30       Impact factor: 3.046

7.  Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits.

Authors:  T Ishii; K Moriyoshi; H Sugihara; K Sakurada; H Kadotani; M Yokoi; C Akazawa; R Shigemoto; N Mizuno; M Masu
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

8.  Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment.

Authors:  A C Chen; B McDonald; S J Moss; H M Gurling
Journal:  Brain Res Mol Brain Res       Date:  1998-02

9.  Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.

Authors:  L W Fitzgerald; A Y Deutch; G Gasic; S F Heinemann; E J Nestler
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

10.  Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.

Authors:  E R Korpi; G Wong; H Lüddens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

View more
  17 in total

Review 1.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 2.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

3.  First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia.

Authors:  Kjetil N Jørgensen; Ragnar Nesvåg; Sindre Gunleiksrud; Andrea Raballo; Erik G Jönsson; Ingrid Agartz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-07       Impact factor: 5.270

4.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.

Authors:  Nina Segnitz; Thomas Ferbert; Andrea Schmitt; Peter Gass; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

5.  Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia.

Authors:  A Schmitt; M Fendt; M Zink; U Ebert; M Starke; M Berthold; A Herb; G Petroianu; P Falkai; F A Henn
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

6.  Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study.

Authors:  Monika Vrajová; Frantisek Stastný; Jirí Horácek; Jan Lochman; Omar Serý; Sona Peková; Jan Klaschka; Cyril Höschl
Journal:  Neurochem Res       Date:  2010-03-05       Impact factor: 3.996

7.  The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.

Authors:  Martina von Wilmsdorff; Marie-Luise Bouvier; Uwe Henning; Andrea Schmitt; Wolfgang Gaebel
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex.

Authors:  Maile A Henson; Adam C Roberts; Kayvon Salimi; Swarooparani Vadlamudi; Robert M Hamer; John H Gilmore; L Fredrik Jarskog; Benjamin D Philpot
Journal:  Cereb Cortex       Date:  2008-02-21       Impact factor: 5.357

9.  The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.

Authors:  Ghada S Mahmoud; Ghada Hosny; Sally A Sayed
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-04-15

10.  Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia.

Authors:  Andrea Schmitt; Jiri Koschel; Mathias Zink; Manfred Bauer; Clemens Sommer; Josef Frank; Jens Treutlein; Thomas Schulze; Thomas Schneider-Axmann; Eleni Parlapani; Marcella Rietschel; Peter Falkai; Fritz A Henn
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.